BriaCell Therapeutics Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BCTX research report →
Price Chart
About the company
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation.
- CEO
- William V. Williams
- IPO
- 2012
- Employees
- 16
- HQ
- West Vancouver, BC, CA
Get TickerSpark's AI analysis on BCTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $34.97M
- P/E
- -0.33
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 1.22
- EV/EBITDA
- -0.90
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -147.92%
- ROIC
- -136.31%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-147,888-79.1%
- Op Income
- $-37,732,298
- Net Income
- $-36,493,821-661.4%
- EPS
- $-62.60-45.5%
- OCF Growth
- -18.5%
- FCF Growth
- -16.3%
- 52W High
- $14.68
- 52W Low
- $2.60
- 50D MA
- $3.73
- 200D MA
- $4.21
- Beta
- 1.52
- RSI (14)
- 52
- Avg Volume
- 288.06K
No earnings-call transcripts are available for BCTX yet.
- Free Float
- 90.3%
- Shares Outstanding
- 8.70M
- Float Shares
- 7.86M
of shares held by institutions
14 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Cable Car Capital LLC | 216.82K | 0 |
| Sabby Management, LLC | 80.72K | ▲ 6.81K |
| Iridian Asset Management LLC/Ct | 65.00K | 0 |
| Ubs Group AG | 43.64K | ▲ 32.10K |
| Hrt Financial LP | 34.90K | ▲ 34.90K |
| Jane Street Group, LLC | 26.52K | ▲ 26.52K |
| Luminarx Capital Management LP | 15.00K | 0 |
| National Bank Of Canada | 1.80K | ▲ 1.00K |
| Morgan Stanley | 1.03K | ▼ 1.99K |
| Federation Des Caisses Desjardins Du Quebec | 450 | ▼ 5 |
| Royal Bank Of Canada | 289 | ▲ 289 |
| Allworth Financial LP | 100 | 0 |
Held by 1 ETFs
Biggest fund positions in BCTX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 14, 24 | Lustig Marc | buy | 902,935 |
| May 14, 24 | Lustig Marc | buy | 902,935 |
| Dec 28, 22 | Bondarenko Jamieson | buy | 28,000 |
| Dec 23, 22 | Williams William V. | buy | 2,530 |
| Dec 20, 22 | Bondarenko Jamieson | buy | 22,000 |
| Aug 1, 22 | Bondarenko Jamieson | other | 0 |
| Mar 29, 21 | Bondarenko Jamieson | other | 150,000 |
| Aug 1, 22 | Bondarenko Jamieson | other | 250,000 |
| Aug 12, 21 | Bondarenko Jamieson | other | 70,000 |
| Aug 1, 22 | Lustig Marc | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BCTX coverage
Recent articles, reports, and earnings notes.
No research on BCTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BCTX report →BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting
globenewswire.com · Oct 6
Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study
globenewswire.com · Sep 14
BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center
globenewswire.com · Sep 8
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™
globenewswire.com · Aug 24
BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer
globenewswire.com · Aug 5
BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer
globenewswire.com · Jul 16
BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™
globenewswire.com · Jul 15
BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™
globenewswire.com · Jul 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.